TKNO
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Alpha Teknova, Inc. (TKNO) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (2.9) | C+ (2.7) | B- (3.0) | A (4.2) | C+ (2.6) | B- (3.1) |
| 2026-11-08 | B- (3.0) | C+ (2.5) | B- (3.0) | A (4.3) | A+ (5.0) | B+ (3.6) |
| 2026-11-01 | B- (3.0) | C (2.4) | B- (3.0) | A+ (4.6) | A+ (5.0) | B+ (3.6) |
| 2026-10-25 | B- (3.0) | C (2.4) | B- (3.0) | A+ (4.5) | A+ (5.0) | B+ (3.6) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe